ArticleIrish journal of medical science2026
Effects of tyrosine kinase inhibitors in treatment of non small cell lung cancer patients with brain metastases, real world experience.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains one of the leading causes of cancer-related mortality worldwide, and brain metastases are a common and serious complication of advanced disease. Early detection and effective management of brain metastases are essential for improving survival and maintaining quality of life. Recent advances in targeted therapies, particularly tyrosine kinase inhibitors (TKIs), have shown promising efficacy in controlling both systemic and intracranial disease. This study aimed to evaluate the efficacy of TKIs in patients with non-small cell lung cancer (NSCLC) harboring driver mutations and presenting with brain metastases. MATERIALS AND
methodsWe retrospectively analyzed 31 patients with NSCLC and brain metastases who received targeted therapy at Karadeniz Technical University Faculty of Medicine between January 1, 2010, and September 1, 2023. Clinical and demographic data, including age, sex, histological and molecular subtypes, metastatic sites, progression-free survival (PFS), overall survival (OS), and treatment modalities, were evaluated.
resultsMedian OS was 34.5 months in patients with PD-L1 expression < 50%, compared with 4.5 months in those with PD-L1 expression ≥ 50% (p = 0.004). Median OS was 36.1 months (range, 1.8-58.7) among never-smokers and 4.5 months (range, 2.2-18.5) among current or former smokers (p = 0.005).
conclusionTKIs remain an effective treatment option for patients with NSCLC and brain metastases. PD-L1 expression and smoking status may influence clinical outcomes. Further studies are warranted to validate these findings and clarify the prognostic role of PD-L1 expression in NSCLC patients with brain metastases.
Indexed as
Identifiers
42862446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.